More News

FDA Breakthrough Therapy Designation for spinal muscular atrophy treatment

Jim Cornall -
Biogen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for...

Servier acquiring Edgewise Therapeutics’ muscular dystrophy business

Jim Cornall -
Servier has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. for up to...

Antibody fragment prevents haemorrhages associated with new Alzheimer’s treatments

Jim Cornall -
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (Kisunla,...

Fast Track Designation for Lynch syndrome-associated cancers treatment

Jim Cornall -
Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, has announced that the U.S....

Positive data from linear IgA disease study

Jim Cornall -
JJP Biologics has announced positive interim data from its ongoing phase 1b trial evaluating nebaprubart, also known as JJP-1212,...

Base to Base biotech podcast 62: A new approach to strokes

Jim Cornall -
This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a...

Blood and biomarker testing service launches in Scotland for earlier Alzheimer’s diagnosis

Jim Cornall -
Scottish Brain Sciences (SBS) has launched a new and accredited clinical laboratory service offering blood‑based biomarker and cerebrospinal fluid...

Partnership looks to accelerate next‑generation brain treatments

Jim Cornall -
Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Medicines Discovery Catapult (MDC), a life sciences service dedicated...

Positive results for C. difficile vaccine

Jim Cornall -
Idorsia Ltd has announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a...

Positive results from regenerative cardiac patch platform

Jim Cornall -
Repairon, a biotechnology company developing regenerative cardiac therapies, has announced that clinical results evaluating its engineered human heart muscle...

First human SMUG1 structures reveal how cells repair DNA

Jim Cornall -
Researchers have captured the first atomic structures of human SMUG1, an enzyme that helps cells repair damaged DNA. The findings...

Positive results from kidney transplantation study

Jim Cornall -
Hansa Biopharma AB has announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label...

New Tourette syndrome drug shows promise in phase III trial

Jim Cornall -
Continued use of a drug called ecopipam can cut the risk of relapse in half for children battling tics...

Collaboration to advance clinical trial platform for colorectal cancer

Jim Cornall -
The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research (GCAR) have announced a strategic collaboration to establish...

New peptides slip into cells to block hard-to-target proteins

Jim Cornall -
Many diseases are driven by proteins interacting with each other inside cells. But blocking these interactions with drugs is...

Lung cancer cells switch identity to resist treatment

Jim Cornall -
Cancer scientists have discovered that lung cancer cells can change their identity to resist treatment. Research published in Molecular Oncology...

Could anaemia drug have potential as cancer treatment?

Jim Cornall -
Common medications used to treat anaemia may also slow down cancer cell growth, according to new research from Finland. Researchers...

Base to Base biotech podcast 61: Making tumours visible, and taking on tough challenges

Jim Cornall -
This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO...

Paediatric pneumococcal vaccine programme advancing

Jim Cornall -
Pfizer Inc. has announced data from its phase 2 study evaluating the safety, tolerability and immunogenicity of a four-dose...

FDA clearance for universal dual-target CAR-T candidate

Jim Cornall -
Qihan Biotech’s QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). QT-019C is...

Positive data from chronic scrotal content pain trial

Jim Cornall -
Sustained Therapeutics, Inc. has presented additional data from its phase 2 study evaluating ST-01, a proprietary non-opioid sustained-release small...